1
|
Teoh Z, Simpson BN, Howard T, McElhinney K, Ware R, Mena R, Schlaudecker EP. Codetection of Plasmodium falciparum in Children Hospitalized With Dengue Fever in the Dominican Republic. Pediatr Infect Dis J 2023; 42:965-968. [PMID: 37523515 DOI: 10.1097/inf.0000000000004060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/02/2023]
Abstract
BACKGROUND Cases of malaria and dengue in the Dominican Republic both spiked in 2019, but their rates of codetection are poorly characterized, especially in children. METHODS We performed a prospective, observational study in January to December 2019 at the Hospital Infantil Robert Reid Cabral, in the Dominican Republic, enrolling hospitalized children with a clinical suspicion of dengue fever. Participants with a positive plasma dengue IgM antibodies were included in this study. Clinical and hospital data were abstracted, and dried blood spot samples were collected from participants and tested with quantitative polymerase chain reaction to detect the presence of Plasmodium falciparum DNA. RESULTS A total of 429 children with serological evidence of acute dengue were included in this study, of whom 1.4% (n = 6/429) had codetection of dengue and malaria. There were no significant differences in fever duration or presence of vomiting, abdominal pain and rash between both groups. Children with dengue and malaria codetection were numerically more often admitted to the pediatric intensive care unit, despite no differences found in overall clinical severity. CONCLUSIONS The codetection of malaria and dengue in children was overall uncommon in our Dominican Republic cohort despite the rise in cases in 2019 but may be associated with a more severe hospital course. Further epidemiological and cohort studies to characterize the risk of both pathogens as case numbers fluctuate will be important to better understand the dynamics of coinfections.
Collapse
Affiliation(s)
- Zheyi Teoh
- From the Division of Infectious Diseases
| | - Brittany N Simpson
- Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | | | | | - Russell Ware
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
- Division of Hematology CBDI
- Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Rafael Mena
- Centro de Obstetricia y Ginecología, Hospital Infantil Robert Reid Cabral, Santo Domingo, Dominican Republic
| | - Elizabeth P Schlaudecker
- From the Division of Infectious Diseases
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
- Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| |
Collapse
|
2
|
Smart LR, Charles M, McElhinney KE, Dong M, Power-Hays A, Howard T, Vinks AA, Ambrose EE, Ware RE. Hydroxyurea pharmacokinetics and precision dosing in low-resource settings. Front Mol Biosci 2023; 10:1130206. [PMID: 37325474 PMCID: PMC10267409 DOI: 10.3389/fmolb.2023.1130206] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 05/22/2023] [Indexed: 06/17/2023] Open
Abstract
Introduction: Hydroxyurea is effective disease-modifying treatment for sickle cell anemia (SCA). Escalation to maximum tolerated dose (MTD) achieves superior benefits without additional toxicities, but requires dose adjustments with serial monitoring. Pharmacokinetic (PK)-guided dosing can predict a personalized optimal dose, which approximates MTD and requires fewer clinical visits, laboratory assessments, and dose adjustments. However, PK-guided dosing requires complex analytical techniques unavailable in low-resource settings. Simplified hydroxyurea PK analysis could optimize dosing and increase access to treatment. Methods: Concentrated stock solutions of reagents for chemical detection of serum hydroxyurea using HPLC were prepared and stored at -80C. On the day of analysis, hydroxyurea was serially diluted in human serum, then spiked with N-methylurea as an internal standard and analyzed using two commercial HPLC machines: 1) standard benchtop Agilent with 449 nm detector and 5 micron C18 column; and 2) portable PolyLC with 415 nm detector and 3.5 micron C18 column. After validation in the United States, the portable HPLC and chemicals were transported to Tanzania. Results: A calibration curve using hydroxyurea 2-fold dilutions ranging from 0 to 1000 µM was plotted against the hydroxyurea:N-methylurea ratio. In the United States, both HPLC systems yielded calibration curves with R2 > 0.99. Hydroxyurea prepared at known concentrations confirmed accuracy and precision within 10%-20% of the actual values. Both HPLC systems measured hydroxyurea with <10% variance from the prepared concentrations, and paired analysis of samples on both machines documented <15% variance. Serial measurements of 300 and 100 μM concentrations using the PolyLC system were precise with 2.5% coefficient of variance. After transport to Tanzania with setup and training, the modified PolyLC HPLC system produced similar calibration curves with R2 > 0.99. Conclusion: Increasing access to hydroxyurea for people with SCA requires an approach that eases financial and logistical barriers while optimizing safety and benefits, especially in low-resource settings. We successfully modified a portable HPLC instrument to quantify hydroxyurea, validated its precision and accuracy, and confirmed capacity building and knowledge transfer to Tanzania. HPLC measurement of serum hydroxyurea is now feasible in low-resource settings using available laboratory infrastructure. PK-guided dosing of hydroxyurea will be tested prospectively to achieve optimal treatment responses.
Collapse
Affiliation(s)
- Luke R Smart
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
- Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
| | - Mwesige Charles
- Department of Laboratory Sciences, Bugando Medical Centre, Mwanza, Tanzania
| | - Kathryn E McElhinney
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
| | - Min Dong
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
- Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
| | - Alexandra Power-Hays
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
- Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
| | - Thad Howard
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
| | - Alexander A Vinks
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
- Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
| | - Emmanuela E Ambrose
- Department of Paediatrics and Child Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania
- Department of Paediatrics and Child Health Bugando Medical Centre, Mwanza, Tanzania
| | - Russell E Ware
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
- Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
| |
Collapse
|
3
|
Torous DK, Avlasevich S, Bemis JC, Howard T, Ware RE, Fung C, Chen Y, Sahsrabudhe D, MacGregor JT, Dertinger SD. Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients. Environ Mol Mutagen 2023; 64:167-175. [PMID: 36841969 DOI: 10.1002/em.22536] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Revised: 02/20/2023] [Accepted: 02/22/2023] [Indexed: 05/03/2023]
Abstract
Hydroxyurea is approved for treating children and adults with sickle cell anemia (SCA). Despite its proven efficacy, concerns remain about its mutagenic and carcinogenic potential that hamper its widespread use. Cell culture- and animal-based investigations indicate that hydroxyurea's genotoxic effects are due to indirect clastogenicity in select cell types when high dose and time thresholds are exceeded (reviewed by Ware & Dertinger, 2021). The current study extends these preclinical observations to pediatric patients receiving hydroxyurea for treatment of SCA. First, proof-of-principle experiments with testicular cancer patients exposed to a cisplatin-based regimen validated the ability of flow cytometric blood-based micronucleated reticulocyte (MN-RET) and PIG-A mutant reticulocyte (MUT RET) assays to detect clastogenicity and gene mutations, respectively. Second, these biomarkers were measured in a cross-sectional study with 26 SCA patients receiving hydroxyurea and 13 SCA patients without exposure. Finally, a prospective study was conducted with 10 SCA patients using pretreatment blood samples and after 6 or 12 months of therapy. Cancer patients exposed to cisplatin exhibited increased MN-RET within days of exposure, while the MUT RET endpoint required more time to reach maximal levels. In SCA patients, hydroxyurea induced MN-RET in both the cross-sectional and prospective studies. However, no evidence of PIG-A gene mutation was found in hydroxyurea-treated children, despite the fact that the two assays use the same rapidly-dividing, highly-exposed cell type. Collectively, these results reinforce the complementary nature of MN-RET and MUT RET biomarkers, and indicate that hydroxyurea can be clastogenic but was not mutagenic in young patients with SCA.
Collapse
Affiliation(s)
| | | | | | - Thad Howard
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - Russell E Ware
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - Chunkit Fung
- J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA
| | - Yuhchyau Chen
- J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA
| | - Deepak Sahsrabudhe
- J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA
| | | | | |
Collapse
|
4
|
Macharia AW, Mochamah G, Makale J, Howard T, Mturi N, Olupot-Olupot P, Färnert A, Ware RE, Williams TN. Case Report: β-thalassemia major on the East African coast. Wellcome Open Res 2022; 7:188. [PMID: 37811313 PMCID: PMC10551670 DOI: 10.12688/wellcomeopenres.17907.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/08/2022] [Indexed: 10/10/2023] Open
Abstract
Background: β-thalassemia is rare in sub-Saharan Africa and to our knowledge there has been no case of homozygous β-thalassemia major reported from this region. In a recent cohort study, we identified four β-thalassemia mutations among 83 heterozygous carriers in Kilifi, Kenya. One of the mutations identified was a rare β-globin gene initiation codon mutation (ATG➝ACG) (rs33941849). Here we present a patient with β-thalassemia major resulting from this mutation, only the second homozygous patient to have been reported. Methods: The female patient presented to Kilifi County Hospital aged two years with a one week left sided abdominal swelling. Clinical, hematological and genetic information were collected at admission and follow-up. Results: Admission bloods revealed marked anemia, with a hemoglobin (Hb) value of 6.6 g/dL and a low mean corpuscular volume of 64 fL. High performance liquid chromatography (HPLC) revealed the absence of HbA0 and elevated levels of HbF, suggesting a diagnosis of β-thalassemia major. Sequencing revealed that the child was homozygous for the rs33941849 initiation codon mutation. Conclusions: We hope that this study will create awareness regarding the presence of β-thalassemia as a potential public health problem in the East Africa region and will prompt the development of local guidelines regarding the diagnosis and management of this condition.
Collapse
Affiliation(s)
- Alexander W. Macharia
- Epidemiology and Demography Department, KEMRI/Wellcome Trust Kilifi, Kilifi, 254, Kenya
| | - George Mochamah
- Epidemiology and Demography Department, KEMRI/Wellcome Trust Kilifi, Kilifi, 254, Kenya
| | - Johnstone Makale
- Epidemiology and Demography Department, KEMRI/Wellcome Trust Kilifi, Kilifi, 254, Kenya
| | - Thad Howard
- Division of Hematology, Cincinnati Children's Hospital Medical Center, OH, USA
| | - Neema Mturi
- Epidemiology and Demography Department, KEMRI/Wellcome Trust Kilifi, Kilifi, 254, Kenya
| | - Peter Olupot-Olupot
- Mbale Clinical Research Institute, Mbale, Uganda
- Busitema University Faculty of Health Sciences, Mbale, Uganda
| | | | - Russell E. Ware
- Division of Hematology, Cincinnati Children's Hospital Medical Center, OH, USA
| | - Thomas N. Williams
- Epidemiology and Demography Department, KEMRI/Wellcome Trust Kilifi, Kilifi, 254, Kenya
- Institute for Global Health Innovation, Imperial College, London, UK
| |
Collapse
|
5
|
Tegha G, Topazian HM, Kamthunzi P, Howard T, Tembo Z, Mvalo T, Chome N, Kumwenda W, Mkochi T, Hernandez A, Ataga KI, Hoffman IF, Ware RE. Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. Int J Public Health 2021; 66:629338. [PMID: 34335138 PMCID: PMC8284589 DOI: 10.3389/ijph.2021.629338] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 06/11/2021] [Indexed: 11/13/2022] Open
Abstract
Objectives: Newborn screening in the United States and Europe allows early identification of congenital disorders but does not yet exist in most low-resource settings, especially in sub-Saharan Africa. Newborn screening can identify multiple inherited hematological disorders, but feasibility and effectiveness for Africa are not fully determined. Methods: Surplus dried blood spot collected in Central Malawi through the HIV Early Infant Diagnosis surveillance program were repurposed and tested by isoelectric focusing for sickle cell disease and trait. Additional genetic testing identified G6PD deficiency and alpha thalassemia. Results: Testing of 10,529 cards revealed an overall sickle cell trait prevalence of 7.0% (range 3.9-9.7% by district); 10 of 14 infants identified with sickle cell disease (prevalence 0.1%) were located and received care at a specialized clinic. Subsequent testing of 1,329 randomly selected cards identified alpha thalassemia trait in 45.7% of samples, and G6PD deficiency in 20.4% of males and 3.4% of females, with 29.0% of females as heterozygous carriers. Conclusion: Inherited hematological disorders are common in Central Malawi; early identification through newborn screening can improve clinical outcomes and should be supported throughout Africa.
Collapse
Affiliation(s)
- Gerald Tegha
- University of North Carolina Project-Malawi, Lilongwe, Malawi
| | - Hillary M. Topazian
- University of North Carolina Project-Malawi, Lilongwe, Malawi
- Department of Epidemiology, University of North Carolina, Chapel Hill, NC, United States
| | - Portia Kamthunzi
- University of North Carolina Project-Malawi, Lilongwe, Malawi
- Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, United States
| | - Thad Howard
- Division of Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| | - Zondwayo Tembo
- University of North Carolina Project-Malawi, Lilongwe, Malawi
| | - Tisungane Mvalo
- University of North Carolina Project-Malawi, Lilongwe, Malawi
- Department of Pediatrics, University of North Carolina, Chapel Hill, NC, United States
| | - Nelecy Chome
- University of North Carolina Project-Malawi, Lilongwe, Malawi
| | - Wiza Kumwenda
- University of North Carolina Project-Malawi, Lilongwe, Malawi
| | - Tawonga Mkochi
- University of North Carolina Project-Malawi, Lilongwe, Malawi
| | - Arielle Hernandez
- Division of Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| | - Kenneth I. Ataga
- Center for Sickle Cell Disease, The University of Tennessee Health Science Center, Memphis, TN, United States
| | - Irving F. Hoffman
- University of North Carolina Project-Malawi, Lilongwe, Malawi
- Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, United States
| | - Russell E. Ware
- Division of Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
- Global Health Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| |
Collapse
|
6
|
Forzano LB, Sorama M, O'Keefe M, Pizzonia K, Howard T, Dukic N. Impulsivity and self-control in elementary school children and adult females: Using identical task and procedural parameters. Behav Processes 2021; 188:104411. [PMID: 33910032 DOI: 10.1016/j.beproc.2021.104411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 04/20/2021] [Accepted: 04/21/2021] [Indexed: 11/28/2022]
Abstract
Results of studies examining the relationship between impulsivity and age are limited because different tasks, procedural parameters, and different reinforcers have been used with different aged participants. Thus, the current study sought to rectify these differences in two experiments with children (42, ages 5-12) and adults (69 college-aged females) using the same task with identical procedural parameters. In the Self-Control Video Software Task (SCVST; Forzano and Schunk, 2008; Forzano et al., 2014) participants repeatedly choose between larger, more delayed and smaller, less delayed access to viewing video cartoons. No differences in impulsivity were found between adults and children. No age or gender differences were found among children. Differences in task and procedural parameters are identified as important in their implications for research on impulsivity.
Collapse
Affiliation(s)
- L B Forzano
- Department of Psychology, SUNY Brockport, United States.
| | - M Sorama
- Department of Psychology, Kyoto Notre Dame University, Kyoto, Japan
| | - M O'Keefe
- Department of Psychology, SUNY Brockport, United States
| | - K Pizzonia
- Department of Psychology, SUNY Brockport, United States
| | - T Howard
- Department of Psychology, SUNY Brockport, United States
| | - N Dukic
- Department of Psychology, SUNY Brockport, United States
| |
Collapse
|
7
|
Lynch A, Ahuja S, Miron A, Nakano S, Howard T, Villa C, Armstrong K, Kaufman B, Gardin L, Whitehill R, Parent J, Godown J, Henderson H, Aziz P, Colan S, Seshadri B, Kantor P, Russell M, Lal A, Butts R, Richmond M, Conway J, Weintraub R, Rossano J, Mital S. Sudden Cardiac Death and ICD Use in Rasopathy-Associated Hypertrophic Cardiomyopathy. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.1821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Qu L, Howard T, Poyet C, Davis N, Bolton D, Al-Shawi M, Jack G. Does biopsy approach affect histopathology grade concordance from biopsy to prostatectomy? An Australian analysis. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32663-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
9
|
Mullin M, Howard T, Dhillon G, Digby G. MA24.07 Impact of Radiologist Recommendations on Timeliness of Lung Cancer Referral: Baseline Data to Guide a Quality Improvement Initiative. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
O'Reilly GM, Mathew J, Roy N, Gupta A, Joshipura M, Sharma N, Mitra B, Cameron PA, Fahey M, Howard T, Kumar V, Jarwani B, Soni KD, Thakor A, Dharap S, Patel P, Jhakal A, Farrow NC, Misra MC, Gruen RL, Fitzgerald MC. A checklist for trauma quality improvement meetings: A process improvement study. Injury 2019; 50:1599-1604. [PMID: 31040028 DOI: 10.1016/j.injury.2019.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 03/22/2019] [Accepted: 04/06/2019] [Indexed: 02/02/2023]
Abstract
BACKGROUND Each year approximately five million people die from injuries. In countries where systems of trauma care have been introduced, death and disability have decreased. A major component of developed trauma systems is a trauma quality improvement (TQI) program and trauma quality improvement meeting (TQIM). Effective TQIMs improve trauma care by identifying and fixing problems. But globally, TQIMs are absent or unstructured in most hospitals providing trauma care. The aim of this study was to implement and evaluate a checklist for a structured TQIM. METHODS This project was conducted as a prospective before-and-after study in four major trauma centres in India. The intervention was the introduction of a structured TQIM using a checklist, introduced with a workshop. This workshop was based on the World Health Organization (WHO) TQI Programs short course and resources, plus the developed TQIM checklist. Pre- and post-intervention data collection occurred at all meetings in which cases of trauma death were discussed. The primary outcome was TQIM Checklist compliance, defined by the discussion of, and agreement upon each of the following: preventability of death, identification of opportunities to improve care and corrective actions and a plan for closing the loop. RESULTS There were 34 meetings in each phase, with 99 cases brought to the pre-intervention phase and 125 cases brought to the post-intervention phase. There was an increase in the proportion of cases brought to the meeting for which preventability of death was discussed (from 94% to 100%, p = 0.007) and agreed (from 7 to 19%, OR 3.7; 95% CI:1.4-9.4, p = 0.004) and for which a plan for closing the loop was discussed (from 2% to 18%, OR 10.9; 95% CI:2.5-47.6, p < 0.001) and agreed (from 2% to 18%, OR 10.9; 95% CI:2.5-47.6, p < 0.001). CONCLUSION This study developed, implemented and evaluated a TQIM Checklist for improving TQIM processes. The introduction of a TQIM Checklist, with training, into four Indian trauma centres, led to more structured TQIMs, including increased discussion and agreement on preventability of death and plans for loop closure. A TQIM Checklist should be considered for all centres managing trauma patients.
Collapse
Affiliation(s)
- G M O'Reilly
- National Trauma Research Institute, The Alfred, Melbourne, Australia; Emergency and Trauma Centre, The Alfred, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
| | - J Mathew
- National Trauma Research Institute, The Alfred, Melbourne, Australia; Emergency and Trauma Centre, The Alfred, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia; Trauma Service, The Alfred, Melbourne, Australia
| | - N Roy
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; WHO Collaborating Centre for Research in Surgical Care Delivery in LMICs, BARC Hospital (Govt of India), Mumbai, India
| | - A Gupta
- Division of Trauma Surgery and Critical Care, All India Institute of Medical Sciences, New Delhi, India
| | - M Joshipura
- Academy of Traumatology (India), Ahmedabad, India
| | - N Sharma
- Department of Surgery, All India Institute of Medical Sciences, Jodhpur, India
| | - B Mitra
- National Trauma Research Institute, The Alfred, Melbourne, Australia; Emergency and Trauma Centre, The Alfred, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - P A Cameron
- National Trauma Research Institute, The Alfred, Melbourne, Australia; Emergency and Trauma Centre, The Alfred, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - M Fahey
- Central Clinical School, Monash University, Melbourne, Australia; Tasmanian Health Service, Australia
| | - T Howard
- National Trauma Research Institute, The Alfred, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia
| | - V Kumar
- Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, India
| | - B Jarwani
- Smt. NHL Municipal Medical College, Ahmedabad, India
| | - K D Soni
- Division of Trauma Surgery and Critical Care, All India Institute of Medical Sciences, New Delhi, India
| | - A Thakor
- Smt. NHL Municipal Medical College, Ahmedabad, India
| | - S Dharap
- Topiwala National Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India
| | - P Patel
- Smt. NHL Municipal Medical College, Ahmedabad, India
| | - A Jhakal
- Emergency Department, J.P.N.A. Trauma Center, All India Institute of Medical Sciences, New Delhi, India
| | - N C Farrow
- Central Clinical School, Monash University, Melbourne, Australia; Safer Care Victoria, Melbourne, Australia
| | - M C Misra
- Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, India
| | - R L Gruen
- College of Health and Medicine, Australian National University, Canberra, Australia
| | - M C Fitzgerald
- National Trauma Research Institute, The Alfred, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia; Trauma Service, The Alfred, Melbourne, Australia
| |
Collapse
|
11
|
Ancillotto L, Studer V, Howard T, Smith VS, McAlister E, Beccaloni J, Manzia F, Renzopaoli F, Bosso L, Russo D, Mori E. Environmental drivers of parasite load and species richness in introduced parakeets in an urban landscape. Parasitol Res 2018; 117:3591-3599. [PMID: 30167793 DOI: 10.1007/s00436-018-6058-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 08/15/2018] [Indexed: 11/24/2022]
Abstract
Introduced species represent a threat to native wildlife worldwide, due to predation, competition, and disease transmission. Concurrent introduction of parasites may also add a new dimension of competition, i.e. parasite-mediated competition, through spillover and spillback dynamics. Urban areas are major hotspots of introduced species, but little is known about the effects of urban habitat structure on the parasite load and diversity of introduced species. Here, we investigated such environmental effects on the ectoparasite load, richness, and occurrence of spillback in two widespread invasive parakeets, Psittacula krameri and Myiopsitta monachus, in the metropolitan area of Rome, central Italy. We tested 231 parakeets and found that in both species parasite load was positively influenced by host abundance at local scale, while environmental features such as the amount of natural or urban habitats, as well as richness of native birds, influenced parasite occurrence, load, and richness differently in the two host species. Therefore, we highlight the importance of host population density and habitat composition in shaping the role of introduced parakeets in the spread of both native and introduced parasites, recommending the monitoring of urban populations of birds and their parasites to assess and manage the potential occurrence of parasite-mediated competition dynamics as well as potential spread of vector-borne diseases.
Collapse
Affiliation(s)
- L Ancillotto
- Wildlife Research Unit, Dipartimento di Agraria, Università degli Studi di Napoli Federico II, Naples, Italy
| | - V Studer
- Centro Recupero Fauna Selvatica Lipu Roma, Rome, Italy
| | - T Howard
- Department of Life Sciences, Natural History Museum of London, London, UK
| | - V S Smith
- Department of Life Sciences, Natural History Museum of London, London, UK
| | - E McAlister
- Department of Life Sciences, Natural History Museum of London, London, UK
| | - J Beccaloni
- Department of Life Sciences, Natural History Museum of London, London, UK
| | - F Manzia
- Centro Recupero Fauna Selvatica Lipu Roma, Rome, Italy
| | - F Renzopaoli
- Centro Recupero Fauna Selvatica Lipu Roma, Rome, Italy
| | - L Bosso
- Wildlife Research Unit, Dipartimento di Agraria, Università degli Studi di Napoli Federico II, Naples, Italy
| | - D Russo
- Wildlife Research Unit, Dipartimento di Agraria, Università degli Studi di Napoli Federico II, Naples, Italy. .,School of Biological Sciences, University of Bristol, 24 Tyndall Avenue, Bristol, BS8 1TQ, UK.
| | - E Mori
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via P.A. Mattioli 4, 53100, Siena, Italy.,Accademia Nazionale dei Lincei, Palazzo Corsini, Via della Lungara 10, 00165, Rome, Italy
| |
Collapse
|
12
|
Frank JA, Richert N, Lewis B, Bash C, Howard T, Civil R, Stone R, Eaton J, McFarland H, Leist T. A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients. Mult Scler 2017. [DOI: 10.1177/135245850200800106] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-I (rhIGF-I) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sclerosis (MS) patients. Monthly clinical and MRI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-I. The primary outcome measure was contrast enhancing lesion (CEL) frequency on treatment compared to baseline. Secondary outcome measures included clinical and MRI measures of disease activity including. white matter lesion load (WMLL), magnetization transfer ratio (MTR), TI-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regional metabolite ratios. rhIGF-I (Cephalon) was administered at a dose of 50 mg subcutaneously twice a day for 6 months. rhIGF-I was safe and well tolerated with no severe adverse reactions. There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity. Although rhIGF-I did not alter the course of disease in this small cohort of MS patients, the drug was well tolerated. Further studies using rhIGF-I alone or in combination with other therapies may be of value because of the proposed mechanism of action of this growth factor on the oligodendrocyte and remyelination. Multiple Sclerosis (2002)8,24-29
Collapse
Affiliation(s)
- JA Frank
- Laboratory of Diagnostic Radiology Research, National
Institutes of Health, Building 10, Room B1N256, 10 Center Drive MSC 1074,
Bethesda, Maryland 20892, USA
| | - N. Richert
- Laboratory of Diagnostic Radiology Research, National
Institutes of Health, Building 10, Room B1N256, 10 Center Drive MSC 1074,
Bethesda, Maryland 20892, USA
| | - B. Lewis
- Laboratory of Diagnostic Radiology Research, National
Institutes of Health, Building 10, Room B1N256, 10 Center Drive MSC 1074,
Bethesda, Maryland 20892, USA
| | - C. Bash
- Laboratory of Diagnostic Radiology Research, National
Institutes of Health, Building 10, Room B1N256, 10 Center Drive MSC 1074,
Bethesda, Maryland 20892, USA
| | - T. Howard
- Laboratory of Diagnostic Radiology Research, National
Institutes of Health, Building 10, Room B1N256, 10 Center Drive MSC 1074,
Bethesda, Maryland 20892, USA
| | - R. Civil
- Clinical and Regulatory Affairs, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania, USA
| | - R. Stone
- Neuroimmunology Branch, National Institutes of Health,
Building 10, Room B1N256, 10 Center Drive MSC 1074, Bethesda, Maryland, 20892,
USA
| | - J. Eaton
- Neuroimmunology Branch, National Institutes of Health,
Building 10, Room B1N256, 10 Center Drive MSC 1074, Bethesda, Maryland, 20892,
USA
| | - H. McFarland
- Neuroimmunology Branch, National Institutes of Health,
Building 10, Room B1N256, 10 Center Drive MSC 1074, Bethesda, Maryland, 20892,
USA
| | - T. Leist
- Neuroimmunology Branch, National Institutes of Health,
Building 10, Room B1N256, 10 Center Drive MSC 1074, Bethesda, Maryland, 20892,
USA
| |
Collapse
|
13
|
Diego V, Luu B, Almeida M, Hofmann M, Hernandez J, Morelli A, Ameri A, Rajalingam R, Powell J, Maraskovsky E, Blangero J, Howard T. P196 Quantizinghla-class-II (HLACII) peptidomic parameters as immunologically-relevantendophenotypes toimproveimmunogenicity risk prediction for protein therapeutics (“Biologics”) using factor(F) VIII inhibitor development in hemophilia a (HA) as a model. Hum Immunol 2017. [DOI: 10.1016/j.humimm.2017.06.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Closson K, McNeil R, McDougall P, Fernando S, Collins AB, Baltzer Turje R, Howard T, Parashar S. Meaningful engagement of people living with HIV who use drugs: methodology for the design of a Peer Research Associate (PRA) hiring model. Harm Reduct J 2016; 13:26. [PMID: 27717364 PMCID: PMC5054577 DOI: 10.1186/s12954-016-0116-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Accepted: 09/24/2016] [Indexed: 11/25/2022] Open
Abstract
Background Community-based HIV, harm reduction, and addiction research increasingly involve members of affected communities as Peer Research Associates (PRAs)—individuals with common experiences to the participant population (e.g. people who use drugs, people living with HIV [PLHIV]). However, there is a paucity of literature detailing the operationalization of PRA hiring and thus limited understanding regarding how affected communities can be meaningfully involved through low-barrier engagement in paid positions within community-based participatory research (CBPR) projects. We aim to address this gap by describing a low-threshold PRA hiring process. Results In 2012, the BC Centre for Excellence in HIV/AIDS and the Dr. Peter AIDS Foundation collaborated to develop a mixed-method CBPR project evaluating the effectiveness of the Dr. Peter Centre (DPC)—an integrative HIV care facility in Vancouver, Canada. A primary objective of the study was to assess the impact of DPC services among clients who have a history of illicit drug use. In keeping with CBPR principles, affected populations, community-based organizations, and key stakeholders guided the development and dissemination of a low-barrier PRA hiring process to meaningfully engage affected communities (e.g. PLHIV who have a history of illicit drug use) in all aspects of the research project. The hiring model was implemented in a number of stages, including (1) the establishment of a hiring team; (2) the development and dissemination of the job posting; (3) interviewing applicants; and (4) the selection of participants. The hiring model presented in this paper demonstrates the benefits of hiring vulnerable PLHIV who use drugs as PRAs in community-based research. Conclusions The provision of low-barrier access to meaningful research employment described herein attempts to engage affected communities beyond tokenistic involvement in research. Our hiring model was successful at engaging five PRAs over a 2-year period and fostered opportunities for future paid employment or volunteer opportunities through ongoing collaboration between PRAs and a diverse range of stakeholders working in HIV/AIDS and addictions. Additionally, this model has the potential to be used across a range of studies and community-based settings interested in meaningfully engaging communities in all stages of the research process. Electronic supplementary material The online version of this article (doi:10.1186/s12954-016-0116-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- K Closson
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.,BC Centre for Excellence in HID/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada
| | - R McNeil
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
| | - P McDougall
- Dr. Peter AIDS Foundation, Vancouver, Canada
| | - S Fernando
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
| | - A B Collins
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.,BC Centre for Excellence in HID/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada
| | | | - T Howard
- Positive living society and the British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
| | - S Parashar
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada. .,BC Centre for Excellence in HID/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
| |
Collapse
|
15
|
Cox CE, Prati R, Blumencranz P, Allen K, Banull C, Cline M, Howard T, Portillo M, Whitworth P, Funk K, Police A, Lin E, Combs F, Anglin B, King J, Shivers SC. Abstract P3-13-08: A prospective, single-arm, multi-site, clinical evaluation of the SAVI SCOUT® surgical guidance system for the location of non-palpable breast lesions during excision. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-13-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Objectives: The standard preoperative technique for localizing non-palpable breast lesions is wire localization (WL). Radioactive seed localization (RSL) is an alternative approach that addresses a number of clear disadvantages associated with WL but, the adoption of RSL has been impacted by considerable regulatory requirements for the handling of radioactive materials. To advance the progress made with RSL and eliminate issues associated with radioactive components, the SAVI SCOUT® surgical guidance system was developed. SAVI SCOUT is an FDA-cleared medical device that utilizes non-radioactive electromagnetic wave technology to provide real-time guidance during excisional breast procedures. The purpose of this study is to evaluate the performance of SAVI SCOUT in guiding the removal of non-palpable breast lesions.
Methods: Following a 50 patient pilot study that showed SAVI SCOUT to be safe and effective, IRB approval was granted for this prospective, single-arm, multi-site study for women with a non-palpable breast lesion. Pts underwent localization and excision with the SAVI SCOUT system, which consists of an electromagnetic wave reflective device (reflector), handpiece and console. Using mammographic or ultrasound guidance, the reflector was implanted into the target tissue. Before making an incision, the surgeon used the handpiece, which emits electromagnetic waves and infrared light, to detect the location of the reflector and subsequently plan the surgical incision. During the procedure, the surgeon used the handpiece to guide the localization and removal of the reflector along with the surrounding breast tissue. The console provides audible feedback of reflector proximity to the handpiece. Successful reflector placement, localization and retrieval were the primary endpoints.
Results: A total of 61 pts have participated in the study to date, along with 7 surgeons and 9 radiologists across 6 institutions. The reflectors were successfully placed in all pts, including 27 under mammographic guidance and 34 under ultrasound guidance. In 28 cases, the reflectors were placed on the same day as surgery. Otherwise, the reflectors were placed up to 7 days (average 2.9 days) before surgery. Thirteen pts underwent excisional biopsy and 48 pts had a lumpectomy. The intended lesion and reflector were successfully removed in all pts. Reflector migration did not occur and no adverse events occurred. Final pathology is currently available for 52 pts: 8/10 excisional biopsy pts had no invasive or in situ carcinoma identified. For pts with cancer and complete data, 39/39 had clear margins, but one patient was recommended for re-excision due to a close margin (1 mm) for DCIS.
Conclusions: The preliminary data from this prospective, multi-site study show that real-time surgical guidance with SAVI SCOUT is an accurate technique for directing the removal of non-palpable breast lesions and is reproducible at multiple clinical sites. At present, the study has yielded 100% surgical success with a re-excision rate of 3.0%. Ongoing accrual to this clinical evaluation study will validate these findings with planned enrollment of 150 pts at up to 15 total sites.
Citation Format: Cox CE, Prati R, Blumencranz P, Allen K, Banull C, Cline M, Howard T, Portillo M, Whitworth P, Funk K, Police A, Lin E, Combs F, Anglin B, King J, Shivers SC. A prospective, single-arm, multi-site, clinical evaluation of the SAVI SCOUT® surgical guidance system for the location of non-palpable breast lesions during excision. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-13-08.
Collapse
Affiliation(s)
- CE Cox
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - R Prati
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - P Blumencranz
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - K Allen
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - C Banull
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - M Cline
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - T Howard
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - M Portillo
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - P Whitworth
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - K Funk
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - A Police
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - E Lin
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - F Combs
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - B Anglin
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - J King
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - SC Shivers
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| |
Collapse
|
16
|
Kukushkin M, Otto T, Howard T. Value-centric business development: descriptive and prescriptive research into five different companies. Proc Estonian Acad Sci 2015. [DOI: 10.3176/proc.2015.4s.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
17
|
Shapiro R, Chiorean E, Howard T, Cardenes H. Pilot Study using Neoadjuvant Chemoradiotherapy and EGFR-Tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Freed KA, Blangero J, Howard T, Johnson MP, Curran JE, Garcia YR, Lan HC, Abboud HE, Moses EK. The 57 kb deletion in cystinosis patients extends into TRPV1 causing dysregulation of transcription in peripheral blood mononuclear cells. J Med Genet 2011; 48:563-6. [DOI: 10.1136/jmg.2010.083303] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
19
|
Rotty J, Anderson D, Garcia M, Diaz J, Van de Waarsenburg S, Howard T, Dennison A, Lewin SR, Elliott JH, Hoy J. Preliminary assessment of Treponema pallidum-specific IgM antibody detection and a new rapid point-of-care assay for the diagnosis of syphilis in human immunodeficiency virus-1-infected patients. Int J STD AIDS 2011; 21:758-64. [PMID: 21187358 DOI: 10.1258/ijsa.2010.010237] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The aims of the study were to assess whether Treponema pallidum-specific IgM may provide a useful marker of infectious syphilis in human immunodeficiency virus (HIV)-infected patients, and to compare the performance of a prototype IgM-rapid point-of-care test (PoCT) with a standard IgM-enzyme immunoassay (EIA). Twenty samples from HIV-infected patients with untreated syphilis (n = 4 primary syphilis, n = 11 secondary and n = 5 early latent) and 51 follow-up samples at three, six or 12 months after treatment were tested for the presence of IgM with the Mercia-EIA (Microgen Bioproducts Ltd, Camberley, UK) and a prototype PoCT (Select Vaccines Ltd, Melbourne, Australia). Although sample numbers were small, IgM detection by EIA appears to be a reliable marker for untreated syphilis in HIV-infected patients with primary (4/4 IgM-positive) or secondary syphilis (10/11 IgM-positive, 1/11 equivocal). After treatment, IgM was no longer detected after three months in the majority of patients (87%) and was either negative or equivocal in all patients after six and 12 months. The overall sensitivity of the IgM-PoCT was 82% and varied with clinical stage, being highest in secondary (10/10 EIA positives) but lower in primary (2/4 EIA positives) and early latent syphilis (2/3 EIA positives). Overall specificity was 95%. Rapid detection of IgM would enable clinicians to distinguish between past-treated and infectious syphilis and allow for diagnosis and treatment in a single visit.
Collapse
Affiliation(s)
- J Rotty
- Infectious Diseases Unit, Alfred Hospital, Victoria 3181,Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Lawson B, Howard T, Kirkwood JK, Macgregor SK, Perkins M, Robinson RA, Ward LR, Cunningham AA. Epidemiology of salmonellosis in garden birds in England and Wales, 1993 to 2003. Ecohealth 2010; 7:294-306. [PMID: 20945078 DOI: 10.1007/s10393-010-0349-3] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2010] [Revised: 07/12/2010] [Accepted: 07/12/2010] [Indexed: 05/30/2023]
Abstract
Salmonellosis has been reported as an important cause of mortality of garden birds in several countries, including Norway and Scotland. We investigated the frequency of the disease in garden birds submitted for postmortem examination by members of the public in England and Wales between 1993 and 2003, inclusive. We found salmonellosis to be the most frequent cause of death due to infectious disease in the garden birds submitted. This disease was confirmed in 7 of the 45 bird species that were examined postmortem, with the greenfinch (Carduelis chloris) and the house sparrow (Passer domesticus) most frequently affected. Salmonella Typhimurium definitive phage type (DT) 40, DT56 variant(v), and DT160 accounted for the majority of isolates. Salmonellosis incidents chiefly occurred in the English Midlands, the English/Welsh border region, and southern England. Variation in the temporal and spatial distribution of the phage types occurred over the study period. While birds were examined throughout the year, there was a marked winter seasonality in salmonellosis. A significant sex bias was observed in affected greenfinches, with males more frequently diagnosed with salmonellosis than females. No sex bias was observed for other affected species. Further research is required to determine if salmonellosis is an important constraint to the populations of affected species and if disease outbreaks are driven by human factors, such as provisioning.
Collapse
Affiliation(s)
- B Lawson
- Institute of Zoology, Zoological Society of London, Regents Park, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Huffman KM, Sloane R, Peterson MJ, Bosworth HB, Ekelund C, Pearson M, Howard T, Pieper CF, Morey MC. The impact of self-reported arthritis and diabetes on response to a home-based physical activity counselling intervention. Scand J Rheumatol 2010; 39:233-9. [PMID: 20429674 DOI: 10.3109/03009740903348973] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVES Physical activity (PA) has the potential to improve outcomes in both arthritis and diabetes, but these conditions are rarely examined together. Our objective was to explore whether persons with arthritis alone or those with both arthritis and diabetes could improve amounts of PA with a home-based counselling intervention. METHODS As part of the Veterans LIFE (Learning to Improve Fitness and Function in Elders) Study, veterans aged 70-92 were randomized to usual care or a 12-month PA counselling programme. Arthritis and diabetes were assessed by self-report. Mixed models were used to compare trajectories for minutes of endurance and strength training PA for persons with no arthritis (n = 85), arthritis (n = 178), and arthritis plus diabetes (n = 84). RESULTS Recipients of PA counselling increased minutes of PA per week independent of disease status (treatment arm by time interaction p < 0.05 for both; endurance training time p = 0.0006 and strength training time p < 0.0001). Although PA was lower at each wave among persons with arthritis, and even more so among persons with arthritis plus diabetes, the presence of these conditions did not significantly influence response to the intervention (arthritis/diabetes group x time interactions p > 0.05 for both outcomes) as each group experienced a nearly twofold or greater increase in PA. CONCLUSIONS A home-based PA intervention was effective in increasing minutes of weekly moderate intensity endurance and strength training PA in older veterans, even among those with arthritis or arthritis plus diabetes. This programme may serve as a useful model to improve outcomes in older persons with these pervasive diseases.
Collapse
Affiliation(s)
- K M Huffman
- Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Huffman KM, Hall KS, Sloane R, Peterson MJ, Bosworth HB, Ekelund C, Pearson M, Howard T, Pieper CF, Morey MC. Is diabetes associated with poorer self-efficacy and motivation for physical activity in older adults with arthritis? Scand J Rheumatol 2010; 39:380-6. [PMID: 20604671 PMCID: PMC3058748 DOI: 10.3109/03009741003605630] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVES The primary aim was to explore whether arthritis is associated with poorer self-efficacy and motivation for, and participation in, two specific types of physical activity (PA): endurance training (ET) and strength training (ST). A further objective was to determine whether the added burden of diabetes contributes to a further reduction in these PA determinants and types. METHODS Self-efficacy and motivation for exercise and minutes per week of ET and ST were measured in 347 older veterans enrolled in a home-based PA counselling intervention. Regression analyses were used to compare high versus low self-efficacy and motivation and PA minutes in persons without arthritis, with arthritis alone, and with arthritis plus diabetes. RESULTS Persons with arthritis alone reported lower self-efficacy for ET and ST than those without arthritis [odds ratio (OR)ET 0.71, 95% confidence interval (CI) 0.39–1.20; ORST 0.69, 95% CI 0.39–1.20]. A further reduction in self-efficacy for these two types of PA was observed for those with both arthritis and diabetes (ORET 0.65, 95% CI 0.44–0.92; ORST 0.64, 95% CI 0.44–0.93; trend p < 0.001). There was no trend towards a reduction in motivation for PA in those with arthritis alone or with arthritis and diabetes. Persons with arthritis exhibited higher motivation for ET than those without arthritis (ORET 1.85, 95% CI 1.12–3.33). There were no significant differences between the three groups in minutes of ET (p = 0.93), but persons with arthritis plus diabetes reported significantly less ST compared to individuals with arthritis only (p = 0.03). CONCLUSIONS Despite reduced self-efficacy for ET and ST and less ST in older persons with arthritis, motivation for both PA types remains high, even in the presence of diabetes.
Collapse
Affiliation(s)
- K M Huffman
- Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Shetty A, McLauchlin J, Grant K, O'Brien D, Howard T, Davies EM. Outbreak of Listeria monocytogenes in an oncology unit associated with sandwiches consumed in hospital. J Hosp Infect 2009; 72:332-6. [PMID: 19278752 DOI: 10.1016/j.jhin.2009.01.012] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2008] [Accepted: 01/16/2009] [Indexed: 10/21/2022]
Abstract
In May 2003, two adult patients in an oncology unit were diagnosed with listeriosis, and sandwiches consumed in the hospital were identified as a common risk factor. Both patients were infected by the same strain of Listeria monocytogenes. Sandwiches collected from the hospital and external sandwich producer, as well as sites within the manufacturing environment, were contaminated by the same strain of L. monocytogenes. Sandwiches consumed in other hospitals have been associated with small clusters of listeriosis patients in the UK. This report describes the investigations following diagnosis of the two infections, and highlights a more general problem with sandwiches sold in hospitals.
Collapse
Affiliation(s)
- A Shetty
- Cym Taf NHS Trust, Merthyr Tydfil, UK.
| | | | | | | | | | | |
Collapse
|
24
|
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an important cause of hemolytic anemia worldwide. Severely affected patients have chronic hemolysis with exacerbations following oxidative stress. Mutations causing severe chronic non-spherocytic hemolytic anemia (CNSHA) commonly cluster in Exon 10, a region important for protein dimerization. An African-American male presented at age 2 weeks with pallor and jaundice, and was found to have hemolytic anemia with G6PD deficiency. His severe clinical course was inconsistent with the expected G6PD A(-) variant. DNA sequencing revealed two common mutations (A(-)) and a third novel Exon 10 mutation. This inherited haplotype represents a novel triple G6PD coding mutation causing chronic hemolysis.
Collapse
Affiliation(s)
- Jenny McDade
- Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
| | | | | | | | | |
Collapse
|
25
|
Abstract
Hydroxyurea has documented laboratory and clinical efficacy for children with sickle cell anemia (SCA), and has potential to become an effective and inexpensive treatment option for patients in countries with limited resources. Concerns exist, however, regarding product quality and manufacturing variability among different international vendors, particularly for generic formulations. To address these concerns, hydroxyurea capsules from 8 different pharmaceutical sources were analyzed using quantitative chemical and functional assays. All samples had measured values within 20% of expected results, with no significant differences observed among vendors. Generic hydroxyurea formulations represent a potent yet inexpensive therapeutic option for children with SCA worldwide.
Collapse
Affiliation(s)
- Virginia L Harrod
- Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
| | | | | | | | | | | |
Collapse
|
26
|
Cardenes HR, Chiorean EG, Perkins S, DeWitt J, Schmidt CM, Crowell P, Yip-Schneider M, Zyromski N, Cramer H, Howard T. Neoadjuvant gemcitabine, erlotinib, and hypofractionated radiation therapy for potentially resectable pancreatic cancer: A pilot study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15578] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Sikic BI, Wakelee HA, von Mehren M, Lewis N, Calvert AH, Plummer ER, Fox NL, Howard T, Jones SF, Burris HA. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14006] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14006 Background: Lexatumumab (HGS-ETR2) is a fully-human agonistic monoclonal antibody that targets and activates the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2 (TRAIL-R2). TRAIL-R2 is a member of the Tumor Necrosis Factor Receptor (TNFR) superfamily that, when activated, induces apoptosis via the extrinsic pathway. Lexatumumab shows promising anti-tumor activity in preclinical models, particularly in combination with chemotherapeutic agents. Single-agent lexatumumab was well-tolerated in phase I trials. This is the first study of the safety of a TRAIL-R2 agonist in combination with chemotherapy. Methods: Patients for whom gemcitabine, pemetrexed, doxorubicin or FOLFIRI was considered an appropriate treatment received one of the full-dose chemotherapy regimens plus lexatumumab every 2 weeks (for gemcitabine and FOLFIRI) or 3 weeks (for pemetrexed and doxorubicin). Four to 6 patients were treated with 5 mg/kg lexatumumab in each chemotherapy cohort prior to dose escalation to 10 mg/kg. Results: To date, 41 patients with a wide range of cancer types have received 164 courses of lexatumumab over the 2 dose levels. The majority (33/41) received at least 2 courses (range 1 to 19). Lexatumumab was well-tolerated; no dose reductions of lexatumumab were required. Severe adverse events considered at least possibly related to lexatumumab included anemia, fatigue and dehydration. Tumor shrinkage has been observed, including confirmed partial responses (PRs) in the FOLFIRI and doxorubicin arms. Eight patients continue on study. Conclusions: Lexatumumab can be safely administered in combination with a wide range of chemotherapeutic agents. Evaluation of the efficacy of lexatumumab in combination with chemotherapy in Phase 2 trials is warranted. [Table: see text]
Collapse
Affiliation(s)
- B. I. Sikic
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - H. A. Wakelee
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - M. von Mehren
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - N. Lewis
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - A. H. Calvert
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - E. R. Plummer
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - N. L. Fox
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - T. Howard
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - S. F. Jones
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| | - H. A. Burris
- Stanford Univ School of Medcn, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Newcastle, Newcastle, Upon Tyne, United Kingdom; Human Genome Sciences, Rockville, MD; The Sarah Cannon Research Institute, Nashville, TN
| |
Collapse
|
28
|
Howard T, Lloyd J, Raines C. The in vivo activities of phosphoribulokinase and glyceraldehyde phosphate dehydrogenase can be rapidly altered through protein–protein interactions. Comp Biochem Physiol A Mol Integr Physiol 2007. [DOI: 10.1016/j.cbpa.2007.01.614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Patnaik A, Wakelee H, Mita M, Fitzgerald A, Hill M, Fox N, Howard T, Ullrich S, Tolcher A, Sikic B. HGS-ETR2—A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3012] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3012 Background: HGS-ETR2 is a fully-human high-affinity monoclonal antibody that is agonistic to the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2 (TRAIL-R2, DR5). TRAIL-R2 is expressed more widely on the surface of tumor cells than normal cells; binding of HGS-ETR2 to TRAIL-R2 leads to activation of the extrinsic apoptosis pathway. HGS-ETR2 shows anti-tumor activity at doses ≥ 0.3 mg/kg in xenograft models, both as a single agent and in combination with chemotherapeutic agents. Methods: This phase 1, dose-escalation study assessed the safety, tolerability, pharmacokinetics and immunogenicity of HGS-ETR2 administered IV every 14 days in patients with advanced solid tumors. Patients received HGS-ETR2 until disease progression or unacceptable toxicity. Tumor measurements were repeated every 2 months. Results: To date, 31 patients have received 167 courses of HGS-ETR2 over 5 dose levels: 0.1, 0.3, 1.0, 3.0 and 10.0 mg/kg q14 days. The majority (26 of 31) received at least 4 courses. One patient experienced a dose-limiting toxicity of grade 3 hyperamylasemia at the 10 mg/kg dose level. The event was determined to be possibly related to HGS-ETR2 and also possibly related to a nutritional supplement. Stable disease was achieved in 10 patients for 4 to 16 cycles. One patient with chemotherapy-refractive Hodgkin’s disease had a tumor regression of abdominal disease. HGS-ETR2 pharmacokinetics were linear up to 10 mg/kg. At the 10 mg/kg dose, the pharmacokinetics were characterized by a mean (SD) t1/2β of 11 (4) days, CL of 6.0 (0.7) mL/day, and V1 of 47 (8) mL/kg, slightly larger than the plasma volume. The 1.8-fold larger Vss of 85 (27) mL/kg indicates that HGS-ETR2 distributes outside the plasma compartment. Human anti-human antibody formation has not been detected. Conclusions: HGS-ETR2 can be safely administered every 14 days at doses up to and including 10 mg/kg. Further evaluation of HGS-ETR2 is planned, including studies of HGS-ETR2 in combination with chemotherapeutic agents. [Table: see text]
Collapse
Affiliation(s)
- A. Patnaik
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - H. Wakelee
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - M. Mita
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - A. Fitzgerald
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - M. Hill
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - N. Fox
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - T. Howard
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - S. Ullrich
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - A. Tolcher
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| | - B. Sikic
- Cancer Therapy and Research Center, San Antonio, TX; Stanford University School of Medicine, Stanford, CA; Human Genome Sciences, Rockville, MD
| |
Collapse
|
30
|
Lawson B, MacDonald S, Howard T, Macgregor SK, Cunningham AA. Exposure of garden birds to aflatoxins in Britain. Sci Total Environ 2006; 361:124-31. [PMID: 16271383 DOI: 10.1016/j.scitotenv.2005.09.074] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2005] [Revised: 09/22/2005] [Accepted: 09/23/2005] [Indexed: 05/05/2023]
Abstract
Aflatoxins are potent biological toxins that have been shown to exert a range of acute and chronic pathological effects. Multiple mortality events of waterfowl caused by acute aflatoxicosis have been documented in the USA. However, international concern has recently been expressed regarding the potential effects of chronic exposure of wildlife species to low levels of dietary aflatoxin. This study documents for the first time the presence of hepatic aflatoxin residues in British wild birds: two passerine species, the house sparrow (Passer domesticus) and greenfinch (Carduelis chloris). Further research is required to investigate the source of the dietary aflatoxins and their pathological significance, if any, for wild birds in Britain.
Collapse
Affiliation(s)
- B Lawson
- Institute of Zoology, Zoological Society of London, Regent's Park, London, NW1 4RY, UK.
| | | | | | | | | |
Collapse
|
31
|
Richert ND, Howard T, Frank JA, Stone R, Ostuni J, Ohayon J, Bash C, McFarland HF. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 2006; 66:551-6. [PMID: 16505310 DOI: 10.1212/01.wnl.0000197982.78063.06] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To investigate the temporal relationship between inflammation and cerebral atrophy in a longitudinal study of 19 patients with relapsing-remitting multiple sclerosis (RRMS) using serial monthly contrast enhanced MRI examinations and monthly measurements of brain fractional volume (BFV) for an average of 4 (range 2.4 to 10) years. METHODS In this retrospective study, all patients had an active MRI scan at entry with a minimum of two new contrast enhancing lesions (CEL) on baseline MRI examinations. Patients were followed for a minimum of 3 months during a baseline (pretreatment) phase and subsequently followed during treatment with recombinant interferon beta (IFN) and various other immunomodulatory agents. Pre- and post contrast axial images were obtained using 3-mm slice thickness and a gadolinium contrast dose of 0.1 mmol/kg. Monthly CEL were sequentially numbered on hardcopy films and monthly BFV was determined on precontrast T1W images using a semiautomated program. For BFV measurements, all T1W scans were registered to the entry examination, which served as a mask image. Cerebral atrophy was measured as percent brain fractional volume change (PBVC) compared to the entry baseline scan. RESULTS The results demonstrate that cerebral atrophy paralleled that of contrast enhancing lesion accumulation. The correlation between cumulative CEL and PBVC ranged from R2 = 0.47 to 0.81. Immunomodulatory agents that effectively reduced CEL accumulation also slowed the rate of atrophy. CONCLUSIONS The correlation between contrast enhancing lesions (CEL) and atrophy suggests that patients who are not responding to therapy with a decrease in CEL may also be at risk for developing increased atrophy.
Collapse
Affiliation(s)
- N D Richert
- National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892-1400, USA.
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N, Howard T, Bash CN, Frank JA, Stone L, Martin R, Cutter G, McFarland HF. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2006; 65:1071-6. [PMID: 16217061 DOI: 10.1212/01.wnl.0000178984.30534.f9] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Whereas recent data from imaging studies challenge the prevailing notion that multiple sclerosis (MS) is purely an inflammatory disease, pathologic studies suggest differences in the disease processes between individual patients with MS. The ability to dissect the pathophysiologic disease heterogeneity, if it indeed exists, by methodologies that can be applied in vivo is important both for the development of new therapeutics and for the ability to identify the optimal therapy for an individual patient. OBJECTIVE To design a stratification algorithm for patients with MS based on accepted MRI measurements reflective of inflammation and axonal damage/tissue loss and to assess if such MS subgroups retain their intergroup differences long term. METHODS Mathematical modeling was used to select three discriminatory MRI measures for clinical outcome based on the cross-sectional analysis of 71 patients with untreated MS and tested general applicability of the stratification scheme on the independent longitudinal cohort of 71 MS patients. RESULTS By consecutive employment of MRI measures reflective of inflammation and tissue loss, the authors were able to separate MS patients into four clinically meaningful subgroups. The analysis of the longitudinal confirmatory cohort demonstrated persistence of the intergroup differences in selected MRI measures for 8 years. CONCLUSIONS The inflammatory activity and destructiveness of the multiple sclerosis process are to some degree independent of each other, and the successive evaluation of both of these variables can strengthen prediction of clinical outcome in individual patients.
Collapse
Affiliation(s)
- B Bielekova
- Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892-1400, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Recker R, Masarachia P, Santora A, Howard T, Chavassieux P, Arlot M, Rodan G, Wehren L, Kimmel D. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 2005; 21:185-94. [PMID: 15801989 DOI: 10.1185/030079904x20259] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To compare the microarchitecture of iliac crest trabecular bone from women treated for two to three years with alendronate versus that of women treated with placebo. RESEARCH DESIGN AND METHODS Three-dimensional micro-computed tomography (micro-CT; resolution 20 microm) and two-dimensional histomorphometry (resolution 5-7 microm) were used to examine trabecular bone from single transilial biopsies obtained at the completion of clinical trials. MAIN OUTCOME MEASURES Microarchitectural variables, including bone volume, trabecular number, trabecular thickness, and trabecular spacing in specimens from alendronate- and placebo-treated women were examined. Three-dimensional images of trabecular bone from both groups were constructed from CT images. Correlations among variables and between techniques were also calculated. RESULTS Eighty-eight specimens were suitable for evaluation by both techniques. As measured by two-dimensional histomorphometry, bone volume fraction (as a proportion of total volume) and trabecular thickness were significantly greater in alendronate specimens, 17.1 +/- 5.5% vs. 13.4 +/- 5.5% (p = 0.0043) and 127 +/- 29 microm vs. 109 +/- 28 microm (p = 0.0090), respectively, and trabecular spacing was significantly smaller, 729 +/- 227 microm vs. 862 +/- 338 microm (p = 0.005). Micro-CT yielded similar findings: bone volume and trabecular number were significantly greater in alendronate specimens: 19.4 +/- 6.2% vs. 16.2 +/- 6.3% (p = 0.0412) and 1.46(+/-) 0.32 vs. 1.31(+/-) 0.33 per mm (p = 0.0346). Two-dimensional and micro-CT measured characteristics correlated strongly with one another, with Pearson product moment correlation coefficients ranging from 0.60 (for trabecular thickness) to 0.83 (for bone volume). CONCLUSIONS Trabecular microarchitecture of the ilium, whether studied by two- or three-dimensional methods, is better (greater bone volume, greater trabecular thickness, decreased trabecular spacing) after alendronate treatment than after two to three years of treatment with placebo. Bone volume in a trabecular region is strongly correlated to its microarchitecture, suggesting that bone quantity predicts values for these microarchitectural endpoints.
Collapse
Affiliation(s)
- R Recker
- Osteoporosis Research Center, Creighton University, Omaha, NE 68131-2137, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
|
35
|
Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF. Interferon- -1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 2004; 62:719-25. [PMID: 15007120 DOI: 10.1212/01.wnl.0000113765.75855.19] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To determine the effect of interferon-beta-1b (IFNbeta-1b) treatment on total contrast-enhancing lesions (CEL), white matter lesion load (WMLL), and cerebral atrophy (CA) in patients with relapsing-remitting multiple sclerosis (RRMS) using serial monthly MRI. METHODS An open-label baseline-vs-treatment crossover trial was conducted with 30 RRMS patients monitored during a 6-month baseline and up to 36 months on treatment with IFNbeta-1b. Monthly MRI exams and neurologic exams using the Expanded Disability Status Scale (EDSS) were performed. RESULTS The percentage changes from baseline for years 1, 2, and 3 on IFNbeta-1b were as follows: brain volume (BV) = -1.35, -1.48, and -1.68%; CEL = -76.5, -60.1, and -54.7%; WMLL = -12.2, -9.8, and -10.4%. There was no difference in the BV, CEL, or WMLL for between-year comparisons, and the decrease in BV from year 1 to years 2 and 3 was less than the change from baseline to year 1. EDSS did increase (p < 0.001) when comparing the last 3 months of baseline (2.8 +/- 2.1) and the last 3 months on IFNbeta-1b (3.6 +/- 2.1). Eleven patients developed neutralizing antibody (NAb) during the study. The effect of IFNbeta-1b on CEL and WMLL was significantly reduced in NAb+ patients compared with NAb- patients (p < 0.003). CONCLUSION IFNbeta-1b decreases contrast-enhancing lesions and white matter lesion load over 3 years on therapy and slows the progression in cerebral atrophy during years 2 and 3.
Collapse
Affiliation(s)
- J A Frank
- Experimental Neuroimaging Section, Lab of Diagnostic Radiology Research, NINDS, NIH, Uniformed Services University of Health Sciences, Bethesda, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Chino K, Hanrahan J, Howard T, Reinert B, Bear DG. 93 SKI AND SNO ONCOGENE EXPRESSION IN RHABDOMYOSARCOMA. J Investig Med 2004. [DOI: 10.1136/jim-52-suppl1-646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Leigh R, Ostuni J, Pham D, Goldszal A, Lewis BK, Howard T, Richert N, McFarland H, Frank JA. Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences. Mult Scler 2002; 8:420-9. [PMID: 12356210 DOI: 10.1191/1352458502ms801oa] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
PURPOSE The purpose of this study was to determine how measures reflecting cerebral atrophy (CA) are influenced by pulse sequence (PS) and segmentation algorithm (SA) used in multiple sclerosis (MS) patients and healthy control (HC)s. METHODS Magnetic resonance imaging (MRI) scans from 10 relapsing-remitting MS (RRMS) patients and five HCs were used to determine the change in brain fractional volume (BFV) over a two-year period. T1-weighted, fluid-attenuated inversion recovery (FLAIR), and proton density (PD)/T2-weighted sequences were analysed Image segmentation to determine brain volume was performed using the following a histogram SA, an adaptive fuzzy c-means algorithm (AFCM), and an adaptive Bayesian segmentation with a K-means clustering. RESULTS Combinations of the SA and PS in MS patents demonstrated significant differences in the per cent change in BFV from baseline. For the combination of PS and SA the per cent change in BFV for year one and year two varied from +2.05% to - 1.6% and +0.79% to -3.11%, respectively. Analysis of the HCs data revealed fluctuations in BFV varying from +0.26% to -0.29%. CONCLUSIONS MRI estimates of CA are dependent on both the type of PS and SA; therefore, the choice of SA technique and PS should be consistent during an MS treatment trial. The progression of CA in MS should only be used as a secondary or tertiary outcome measure in treatment trials until a better understanding of how this measurement is affected by the disease, the image acquisition and analysis techniques.
Collapse
Affiliation(s)
- R Leigh
- Neuroimmunology Branch, National Institutes of Neurological Diseases and Stroke, National Institutes of Health, Clinical Center, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Howard T. Use of an Interactive Computer Tutorial Program to Teach the Management of Congestive Heart Failure. Acad Emerg Med 2002. [DOI: 10.1197/aemj.9.10.1056-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
39
|
Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002; 59:688-94. [PMID: 12221158 DOI: 10.1212/wnl.59.5.688] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To determine the effect of IV methylprednisolone (IVMP) on brain fraction volume (BFV), contrast-enhancing (CE) lesions, and white matter lesion load (WMLL) in patients with relapsing-remitting MS treated for acute exacerbations. BACKGROUND MRI metrics of MS disease activity are being used as outcome measures in early phase treatment trials, however the short-term effects of IVMP treatment on cerebral atrophy are unknown. METHODS Serial monthly MRI were performed in 26 patients enrolled in a baseline vs treatment trial with interferon beta-1b (IFNbeta-1b) who were followed for 3 months before and after IVMP. All 26 patients were evaluated while receiving IFNbeta-1b, and 12 patients were also studied during the baseline stage of the trial (NHx). Acute exacerbations were treated with IVMP (1 g/d) for 3 to 5 days. Precontrast and postcontrast T1-weighted and proton density T2-weighted fast spin-echo images were analyzed. RESULTS Fifty-six acute exacerbations were evaluated. For the 3 months before IVMP, there was no difference in WMLL or BFV compared to month IVMP was administered. There was a significant decrease in BFV at month 1 after IVMP in the IFNbeta-1b and NHx groups. Compared to the month IVMP was administered, there was a difference in the CE lesions for months -3 and -1 prior (p < 0.039) in NHx patients. Following IVMP, CE lesions decreased (p < 0.0004) for months 1, 2, and 3 in both groups, but there was no effect on WMLL. CONCLUSIONS BFV and CE lesions were significantly decreased for 1 month (BFV) and 3 months (CE lesions) following IVMP. Therefore, MRI studies should be delayed by probably at least 2 months following IVMP to avoid a possible confounding steroid effect in a clinical trial.
Collapse
Affiliation(s)
- A B Rao
- Laboratory of Diagnostic Radiology Research, Clinical Center, NIH, Bethesda, MD 20892, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Papiz MZ, Prince SM, Howard T, Cogdell RJ, Isaacs NW. The structure and thermal motion of B800-850 LH2 complex from Rps. Acidophilaat 2.0 Å: functionally relevant motion. Acta Crystallogr A 2002. [DOI: 10.1107/s0108767302088554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
41
|
Sutter B, Wasowicz T, Howard T, Hossner LR, Ming DW. Characterization of iron, manganese, and copper synthetic hydroxyapatites by electron paramagnetic resonance spectroscopy. Soil Sci Soc Am J 2002; 66:1359-1366. [PMID: 12817564 DOI: 10.2136/sssaj2002.1359] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The incorporation of micronutrients (e.g., Fe, Mn, Cu) into synthetic hydroxyapatite (SHA) is proposed for slow release of these nutrients to crops in NASA's Advanced Life Support (ALS) program for long-duration space missions. Separate Fe3+ (Fe-SHA), Mn2+ (Mn-SHA), and Cu2+ (Cu-SHA) containing SHA materials were synthesized by a precipitation method. Electron paramagnetic resonance (EPR) spectroscopy was used to determine the location of Fe3+, Mn2+, and Cu2+ ions in the SHA structure and to identify other Fe(3+)-, Mn(2+)-, and Cu(2+)-containing phases that formed during precipitation. The EPR parameters for Fe3+ (g=4.20 and 8.93) and for Mn2+ (g=2.01, A=9.4 mT, D=39.0 mT and E=10.5 mT) indicated that Fe3+ and Mn2+ possessed rhombic ion crystal fields within the SHA structure. The Cu2+ EPR parameters (g(z)=2.488, A(z)=5.2 mT) indicated that Cu2+ was coordinated to more than six oxygens. The rhombic environments of Fe3+ and Mn2+ along with the unique Cu2+ environment suggested that these metals substituted for the 7 or 9 coordinate Ca2+ in SHA. The EPR analyses also detected poorly crystalline metal oxyhydroxides or metal-phosphates associated with SHA. The Fe-, Mn-, and Cu-SHA materials are potential slow release sources of Fe, Mn, and Cu for ALS and terrestrial cropping systems.
Collapse
Affiliation(s)
- B Sutter
- National Research Council, NASA Ames Research Center, Moffett Field, CA 94035, USA.
| | | | | | | | | |
Collapse
|
42
|
Frank JA, Richert N, Lewis B, Bash C, Howard T, Civil R, Stone R, Eaton J, McFarland H, Leist T. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult Scler 2002; 8:24-9. [PMID: 11936485 DOI: 10.1191/1352458502ms768oa] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients. Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1. The primary outcome measure was contrast enhancing lesion (CEL) frequency on treatment compared to baseline. Secondary outcome measures included dinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), T1-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regional metabolite ratios. rhIGF-1 (Cephalon) was administered at a dose of 50 mg subcutaneously twice a day for 6 months. rhIGF-1 was safe and well tolerated with no severe adverse reactions. There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity. Although rhIGF-1 did not alter the course of disease in this small cohort of MS patients, the drug was well tolerated. Further studies using rhIGF-1 alone or in combination with other therapies may be of value because of the proposed mechanism of action of this growth factor on the oligodendrocyte and remyelination.
Collapse
Affiliation(s)
- J A Frank
- Laboratory of Diagnostic Radiology Research, National Institutes of Health, Bethesda, Maryland 20892-1074, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
BACKGROUND Human CD8+ T cells elicit a vigorous response to allo- or xenogeneic MHC class I molecules. However, the influence of a given MHC-bound peptide to the responding allo- or xenoreactive T cell repertoire is not clear. METHODS In this study, we analyzed individual T cell responses to unique tissue epitopes presented on syngeneic porcine endothelial and lymphoblastoid cells by limiting dilution analysis and analyzed the responding T cell repertoire by T cell receptor beta (TCR Vbeta) chain spectrotyping. RESULTS Both porcine endothelial and lymphoblastoid cells were able to elicit swine leukocyte antigen (SLA) class I restricted and peptide-dependent cytotoxic T lymphocyte (CTL) responses. The responding human CD8+ T cells showed a heterogenous but limited TCR Vbeta gene usage. Interestingly, although a large portion of the selected TCR Vbeta gene usage in response to endothelial and lymphoblastoid cells were shared (i.e., Vbeta-1, 2, 6.1, 13), unique Vbeta usage was noted in T cells that respond to either endothelial (Vbeta-5.3) or lymphoblastoid cells (Vbeta-5.1, 11), suggesting that porcine tissue-specific epitopes play a role in modulating the responding T cell repertoire. Limiting dilution cloning analysis revealed that a majority (89%) of the CTL clones stimulated by porcine endothelial cells recognized shared peptides presented by both endothelial cells and syngeneic lymphoblastoid cells. However, a significant portion (11%) of the CTL clones recognized unique peptides presented only in the context of SLA class I molecules on endothelial cells. CONCLUSION These results provide evidence for the first time that tissue-specific peptides can directly influence T cell repertoire in response to the xenogeneic stimulus.
Collapse
Affiliation(s)
- X C Xu
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA
| | | | | |
Collapse
|
44
|
Rhoderick G, Chu P, Dolin E, Marks J, Howard T, Lytle M, McKenzie L, Altman D. Development of perfluorocarbon (PFC) primary standards for monitoring of emissions from aluminum production. Fresenius J Anal Chem 2001; 370:828-33. [PMID: 11569859 DOI: 10.1007/s002160100883] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
An EPA Voluntary Aluminum Industrial Partnership (VAIP) program has been formed to help US primary producers focus on reducing the emissions of two perfluorocarbons (PFCs), tetrafluoromethane (CF4) and hexafluoroethane (C2F6), during the production of aluminum. To ensure comparability of measurements over space and time, traceability to national sources was desirable. Hence, the EPA approached the NIST to develop a suite of primary standards to cover a mole fraction (concentration) range of 0.1 to 1400 micromol mol(-1) for CF4 and 0.01 to 150 micromol mol(-1) of C2F6. A total of eight gravimetric PFC gas standards were prepared with relative expanded uncertainties of < or = 0.52% (approximately 95% confidence level). These primary standards were ultimately used to assign values to a series of secondary gas standards at three mole-fraction levels with relative expanded uncertainties ranging from +/- 0.7% to 5.3% (approximately 95% confidence level). This series of secondary standards was used within the aluminum industry to calibrate instruments used to make emission measurements. Assignment of values to the secondary standards was performed by use of gas chromatography with flame-ionization detection (GC-FID) and Fourier transform infrared spectrometry (FTIR). Real time pot-line and stack samples from a local aluminum plant were also obtained and sub-samples sent to each participating facility for analysis. The data generated from each facility were sent to NIST for analysis. The maximum difference between the NIST and individual facilities' values for the same sub-sample was +/- 26%.
Collapse
Affiliation(s)
- G Rhoderick
- National Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Qin G, Takenaka T, Telsch K, Kelley L, Howard T, Levade T, Deans R, Howard BH, Malech HL, Brady RO, Medin JA. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci U S A 2001; 98:3428-33. [PMID: 11248095 PMCID: PMC30670 DOI: 10.1073/pnas.061020598] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Fabry disease is a lipid storage disorder resulting from mutations in the gene encoding the enzyme alpha-galactosidase A (alpha-gal A; EC ). We previously have demonstrated long-term alpha-gal A enzyme correction and lipid reduction mediated by therapeutic ex vivo transduction and transplantation of hematopoietic cells in a mouse model of Fabry disease. We now report marked improvement in the efficiency of this gene-therapy approach. For this study we used a novel bicistronic retroviral vector that engineers expression of both the therapeutic alpha-gal A gene and the human IL-2Ralpha chain (huCD25) gene as a selectable marker. Coexpression of huCD25 allowed selective immunoenrichment (preselection) of a variety of transduced human and murine cells, resulting in enhanced intracellular and secreted alpha-gal A enzyme activities. Of particular significance for clinical applicability, mobilized CD34(+) peripheral blood hematopoietic stem/progenitor cells from Fabry patients have low-background huCD25 expression and could be enriched effectively after ex vivo transduction, resulting in increased alpha-gal A activity. We evaluated effects of preselection in the mouse model of Fabry disease. Preselection of transduced Fabry mouse bone marrow cells elevated the level of multilineage gene-corrected hematopoietic cells in the circulation of transplanted animals and improved in vivo enzymatic activity levels in plasma and organs for more than 6 months after both primary and secondary transplantation. These studies demonstrate the potential of using a huCD25-based preselection strategy to enhance the clinical utility of ex vivo hematopoietic stem/progenitor cell gene therapy of Fabry disease and other disorders.
Collapse
Affiliation(s)
- G Qin
- Department of Medicine, University of Illinois, Chicago, IL 60607, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Whiting JF, Martin JE, Cohen D, Woodward R, Singer G, Lowell J, Howard T, Woodle ES, Brennan D, Schnitzler MA. Economic outcome of simultaneous pancreas kidney transplantation compared with kidney transplantation alone. Transplant Proc 2001; 33:1923. [PMID: 11267572 DOI: 10.1016/s0041-1345(00)02814-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- J F Whiting
- University of Cincinnati Medical Center, Cincinnati, Ohio, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Olack BJ, Jaramillo A, Zhang L, Swanson C, Rayan K, Goodnight DM, Kaleem Z, Howard T, Mohanakumar T. The role of indirect antigen recognition in islet xenograft rejection. Transplant Proc 2001; 33:784-5. [PMID: 11267070 DOI: 10.1016/s0041-1345(00)02254-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- B J Olack
- Department of Surgery, Washington University School of Medicine, St. Louis, Montana, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Hayashi RJ, Kraus MD, Patel AL, Canter C, Cohen AH, Hmiel P, Howard T, Huddleston C, Lowell JA, Mallory G, Mendeloff E, Molleston J, Sweet S, DeBaun MR. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001; 23:14-8. [PMID: 11196263 DOI: 10.1097/00043426-200101000-00005] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE To determine whether the morphologic features of posttransplant lymphoproliferative disease (PTLD) correlated to a response to therapy. PATIENTS AND METHODS We reviewed our experience with PTLD in the pediatric population. We identified 32 patients with a total of 36 episodes of PTLD. The diagnosis was confirmed by tissue examination and classified according to the degree of monomorphic features of the lesion. Thirty-four of 36 episodes were managed with immunosuppression reduction, and the patients were assessed for their response to this strategy. Chemotherapy was used to treat 10 of 15 patients who had progressive disease, and their subsequent course was also analyzed. RESULTS Sixteen of 17 (94%) patients with polymorphic morphology responded to immunosuppression reduction compared with only 5 of 17 (29%) patients with monomorphic features (P < 0.001). All of the patients with progressive disease who did not receive additional therapy died. Standard chemotherapy regimens for lymphoma were administered to 10 patients with progressive disease, with a high response rate (90%), durable remissions, and acceptable toxicity. CONCLUSIONS We conclude that the morphologic characteristics of PTLD provide information to potentially help guide treatment strategies in the management of this disease. Standard chemotherapy regimens for malignant lymphoma appear to be a viable treatment option for patients with progressive disease, although further investigation is needed.
Collapse
Affiliation(s)
- R J Hayashi
- Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
McKinnon HD, Howard T. Evaluating the febrile patient with a rash. Am Fam Physician 2000; 62:804-16. [PMID: 10969859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
The differential diagnosis for febrile patients with a rash is extensive. Diseases that present with fever and rash are usually classified according to the morphology of the primary lesion. Rashes can be categorized as maculopapular (centrally and peripherally distributed), petechial, diffusely erythematous with desquamation, vesiculobullous-pustular and nodular. Potential causes include viruses, bacteria, spirochetes, rickettsiae, medications and rheumatologic diseases. A thorough history and a careful physical examination are essential to making a correct diagnosis. Although laboratory studies can be useful in confirming the diagnosis, test results often are not available immediately. Because the severity of these illnesses can vary from minor (roseola) to life-threatening (meningococcemia), the family physician must make prompt management decisions regarding empiric therapy. Hospitalization, isolation and antimicrobial therapy often must be considered when a patient presents with fever and a rash.
Collapse
Affiliation(s)
- H D McKinnon
- Dewitt Army Community Hospital, Fort Belvoir, Virginia 22060, USA
| | | |
Collapse
|
50
|
Olack B, Manna P, Jaramillo A, Steward N, Swanson C, Kaesberg D, Poindexter N, Howard T, Mohanakumar T. Indirect recognition of porcine swine leukocyte Ag class I molecules expressed on islets by human CD4+ T lymphocytes. J Immunol 2000; 165:1294-9. [PMID: 10903729 DOI: 10.4049/jimmunol.165.3.1294] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Xenotransplantation of porcine islets is considered a viable alternative treatment for type 1 diabetes mellitus. Therefore, we characterized human PBL responding to porcine islets both in vitro by coculture and in vivo using SCID mice reconstituted with human PBLs (HuPBL-SCID) and transplanted with porcine islets. T cell lines generated in vitro and graft-infiltrating T cells obtained from HuPBL-SCID mice were CD4+-proliferated specifically to porcine islets cultured with autologous APC. This proliferation was abrogated by an anti-human class II Ab. These T cell lines also proliferated to purified swine leukocyte Ag (SLA) class I molecules in the presence of self-APC, indicating that the primary xenoantigens recognized are peptides derived from SLA. This CD4+ T cell line lysed porcine islets but not splenocytes. CD4+ T cell clones with Th0, Th1, and Th2 cytokine profiles were isolated. The Th0 and Th1 clones lysed porcine islets, whereas the Th2 clone that secreted a large amount of IL-4 was not lytic. These results demonstrate that human T cells responding to porcine islets are primarily CD4+ and recognize porcine xenoantigens by the indirect Ag pathway presentation. These activated T cells produce cytokines that lyse islets. Furthermore, we demonstrate that the major porcine xenoantigens recognized are SLA class I molecules.
Collapse
Affiliation(s)
- B Olack
- Departments ofSurgery and Pathology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | | | | | | | | | | | | | | | |
Collapse
|